BARDA awards $143.5 million contract to Pfenex for development of next generation anthrax vaccine - Outbreak News Today | Outbreak News Today Outbreak News Today
Subscribe: RSS Twitter

Pfenex Inc., announced today it has signed a five year, cost plus fixed fee contract valued at up to $143.5 million with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the advanced development of Px563L, a mutant recombinant protective antigen anthrax vaccine.

Anthrax/CDC

Anthrax/CDC

“This contract for the development of Px563L offers the potential for a dramatic improvement in the rapid production of large amounts of a high value stable recombinant anthrax vaccine for the U. S. Government,” stated Bertrand C. Liang, Chief Executive Officer of Pfenex Inc. “The ability to meet articulated medical countermeasure needs, including fulfillment of the requirements of the Strategic National Stockpile, is a key goal in the program.”

Under the contract, the base period will fund activities related to current Good Manufacturing Practice (cGMP) manufacturing of drug product and a Phase 1a clinical study. Milestone-based option periods include completion of a Phase 1b clinical study, a Phase 2 clinical study and non-clinical efficacy studies as well as manufacturing technology transfer and optimization, process and analytical method validation and consistency lot manufacture. Pfenex believes the successful completion of the activities under this contract could lead to a procurement contract for supply of Px563L to the Strategic National Stockpile.

Related news: 

US government orders $133 million of smallpox vaccine 

Dark Biology: When microbes become the ultimate weapon 

Anthrasil receives FDA approval for the treatment of inhalational anthrax

Leave a Reply

© 2016 Outbreak News Today · Subscribe: RSS Twitter ·